Detalhe da pesquisa
1.
Ibudilast reduces slowly enlarging lesions in progressive multiple sclerosis.
Mult Scler
; 30(3): 369-380, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38286755
2.
Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial.
Mult Scler
; 30(2): 177-183, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38130041
3.
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
N Engl J Med
; 383(6): 546-557, 2020 08 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32757523
4.
Effect of ibudilast on thalamic magnetization transfer ratio and volume in progressive multiple sclerosis.
Mult Scler
; 29(10): 1257-1265, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37537928
5.
The impact of cigarette smoking on cognitive processing speed and brain atrophy in multiple sclerosis.
Mult Scler
; 29(7): 846-855, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37204214
6.
Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension.
Mult Scler
; 29(11-12): 1452-1464, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37691530
7.
Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis.
Mult Scler
; 29(1): 92-106, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36113170
8.
Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.
Lancet
; 398(10306): 1184-1194, 2021 09 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34175020
9.
A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment.
Mult Scler
; 28(5): 817-830, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34449295
10.
Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations.
Mult Scler
; 28(14): 2177-2189, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36000489
11.
Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions.
Mult Scler
; 28(7): 1131-1137, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34994577
12.
Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.
Mult Scler
; 28(10): 1562-1575, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35266417
13.
Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study.
Mult Scler
; 28(11): 1729-1743, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35768939
14.
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
Mult Scler
; 28(12): 1944-1962, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35765217
15.
Intrinsic and Extrinsic Mechanisms of Thalamic Pathology in Multiple Sclerosis.
Ann Neurol
; 88(1): 81-92, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32286701
16.
Early age of onset predicts severity of visual impairment in patients with neuromyelitis optica spectrum disorder.
Mult Scler
; 27(11): 1749-1759, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33403943
17.
Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis.
Mult Scler
; 27(14): 2219-2231, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33769117
18.
Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials.
Eur J Neurol
; 28(11): 3722-3730, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34292643
19.
Perspectives of individuals with multiple sclerosis on discontinuation of disease-modifying therapies.
Mult Scler
; 26(12): 1581-1589, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31368401
20.
Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment.
Mult Scler
; 26(1): 23-37, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31778094